ERBB2 and gastric cancer: Indeed in the present study, the HER2 positivity is based on the breast and gastric cancer HER2 testing criteria, but to consider a pre-specified cut-off value that is routinely used from other tumors to assess the positivity of IHC staining could not identify those CDC cases which may exhibit a response to anti-HER2 therapies.